Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divalproex sodium extended-release add-on therapy for adult complex partial seizures
CTR20242165Phase 3Terminated
- Sponsor
- Yichang Humanwell Pharmaceutical Co., Ltd.
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of divalproex sodium in epilepsy, Focal Onset Epilepsy, sponsored by Yichang Humanwell Pharmaceutical Co., Ltd.. Started Jun 2024; status: terminated.
02
Drugs
divalproex sodium
03
Conditions
epilepsyFocal Onset Epilepsy
Beyond the preview
Go deeper on CTR20242165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242165.